Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Pioneering the Future of Heart Health: Biograph and Caristo Diagnostics Announce First-of-its-Kind U.S. Study to Advance AI-Powered Prevention

This image opens in the lightbox

News provided by

Caristo Diagnostics

30 Sep, 2025, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

The study aims to detect early cardiovascular risk in asymptomatic patients through coronary inflammation detection and plaque quantification using cardiac CT, providing opportunities to prevent and manage heart disease before it occurs

SAN MATEO, Calif. and STAMFORD, Conn., Sept. 30, 2025 /PRNewswire/ -- Biograph, the world's most advanced preventive health and diagnostics clinic, today announced a partnership with Caristo Diagnostics to become the first U.S. clinic to study a novel AI-based preventive cardiac marker in asymptomatic patients, by detecting coronary artery inflammation from cardiac CT scans. This study will be exclusively available to Biograph's Black Tier members that are clinically eligible. Study participants will receive access to Caristo's proprietary CaRi-Heart® and CaRi-PlaqueTM technologies to evaluate whether coronary inflammation alongside plaque characterization can detect early heart disease in asymptomatic patients.

This image opens in the lightbox
Biograph’s advanced CT scanner (pictured) will evaluate Caristo’s proprietary technology to detect coronary artery inflammation and plaque, identifying possible heart disease risks earlier

Why Inflammation Detection Matters

"Early detection of inflammation is crucial, as it often precedes plaque buildup and provides a critical window for preventing disease," said Dr. Michael Doney, Executive Medical Director of Biograph. "By engaging in such a partnership with Caristo, we're better suited to position our members at the forefront of cardiac diagnostics, providing research access to a technology not yet broadly available in the U.S."

Current clinical pathways often fail to identify high risk patients by missing inflammatory disease activity and relying on plaque assessment alone. In fact, twice as many fatal and non-fatal cardiac events occurred in patients without obstructive plaque on coronary computed tomography angiography (CCTA), with CaRi-Heart able to identify these patients up to 10 years in advance, even in the absence of visible plaque [Lancet, 2024]. CaRi-Heart technology is a major breakthrough because it quantifies 'invisible' coronary inflammation on cardiac CT scans, rather than having to wait for patients to develop visible plaque. The CaRi-Heart technology is already approved for use in Europe, and this study will be its first evaluation for U.S. research applications in asymptomatic patients traditionally seen as low risk.

"We selected Biograph as our first U.S. longevity focused partner because of its preventive focus, data-driven approach, and advanced imaging capabilities. With Biograph's highly engaged patient population, this is an ideal partnership to demonstrate the impact of CaRi-Heart technology for early detection and the benefits of long-term heart health," said Professor Keith Channon, Chief Medical Officer of Caristo Diagnostics and Professor of Cardiovascular Medicine at the University of Oxford.

Study Design and Participant Experience
In the initial phase the study will enroll 100 of Biograph's Black Tier members beginning in October. Eligible participants will complete a health history form and consultation before imaging to ensure suitability for the study. Findings are expected to corroborate Caristo's existing studies with CaRi-Heart, in their continued efforts to make early detection available globally.

For Biograph, this initiative supports their ongoing mission to revolutionize healthcare and champion preventive approaches.

For more details on the partnership or to request enrollment in the study, visit www.biograph.com.

About Biograph
Biograph  is on a mission to drive meaningful advances in human healthspan and lifespan. We've created the world's most advanced preventive health and diagnostics clinic, where an intuitive and human-centered environment meets cutting-edge medicine to provide members with exceptional, personalized care that empowers them to take control of their health. We continuously incorporate new research into our method to remain on the cutting edge of medicine, and are committed to giving each of our members exceptional service with an emphasis on human-centered design throughout their Biograph journey. Follow Biograph on X and LinkedIn.

About Caristo Diagnostics
Caristo Diagnostics (www.caristo.com) is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford, Caristo's award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Caristo already received FDA 510(k) clearance for its CaRi-Plaque technology, which quantifies coronary plaque and stenosis based on CCTA scans. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention. For more information, visit caristo.com. Find Caristo online on LinkedIn, YouTube, Instagram, and X.

Photo - https://mma.prnewswire.com/media/2784299/Biograph_Caristo_Diagnostics.jpg
Logo - https://mma.prnewswire.com/media/2784777/Biograph_X_Caristo_Logo.jpg

Modal title

Also from this source

Caristo Congratulates Abcentra for First Patient Dosed Successfully in Phase 2b 'FORTIFY' Clinical Trial Evaluating Orticumab in Patients with Cardiovascular Disease

Caristo Congratulates Abcentra for First Patient Dosed Successfully in Phase 2b 'FORTIFY' Clinical Trial Evaluating Orticumab in Patients with Cardiovascular Disease

Caristo Diagnostics, on a mission to transform the diagnosis and treatment of cardiovascular disease, today, congratulates Abcentra for the...

European Society of Cardiology (ESC) Congress 2025 Late Breaking Results Confirm Caristo FAI-Score™ Technology's Superior and Complementary Predictive Value for Cardiac Death Beyond hsCRP

European Society of Cardiology (ESC) Congress 2025 Late Breaking Results Confirm Caristo FAI-Score™ Technology's Superior and Complementary Predictive Value for Cardiac Death Beyond hsCRP

Caristo Diagnostics, announced the late breaking scientific evidence presented at the 75th annual ESC Congress 2025, confirming CaRi-Heart® Fat...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Medical Equipment

Medical Equipment

Artificial Intelligence

Artificial Intelligence

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • PR Newswire Amplify™
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.